Onxeo SA – admittance to trading and official listing on NASDAQ OMX Copenhagen A/S (secondary listing)


Please be informed that Onxeo SA will be admitted to trading and official listing on NASDAQ OMX Copenhagen. First day of trading is 1 August 2014.

The merger between Onxeo (previously BioAlliance Pharma SA) and Topotarget has been adopted at the companies’ shareholder meetings and approved by the relevant authorities. Topotarget is the dis-continuing company. Onxeo SA has its primary listing on Euronext Paris. 

 

 

ISIN: FR0010095596
Name: Onxeo
Volume: 31,482,333 shares (DKK 7,870,583.25)
Face value: EUR 0.25
Currency: EUR
Trade currency: DKK
Voting rights of listed capital: Full
Financial year: 1 January to 31 December
Unlisted capital: EUR 0
French Organization number: 410 910 095 RCS
Segment: MidCap
Average Daily Turnover: Will be calculated by the French FSA
Short name ONXEO
Orderbook ID: 101775
Market Segment / no OMX CPH Equities / 14
Tick Size /no XCSE Equities, DKK / 7
MIC Code XCSE

 

Industry Classification Benchmark (ICB)

4000 Health Care
4500 Health Care

  

For further information, please contact: Asta Jepsen, Surveillance, tel. +45 33 93 33 66

 


Attachments

Onxeo - IPO 2014 - uk.pdf